Co-Authors
This is a "connection" page, showing publications co-authored by LOIS M RAMONDETTA and SHANNON NEVILLE WESTIN.
Connection Strength
1.374
-
Social factors affecting treatment of cervical cancer: ethical issues and policy implications. Obstet Gynecol. 2008 Mar; 111(3):747-51.
Score: 0.314
-
Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. Am J Obstet Gynecol. 2021 02; 224(2):191.e1-191.e15.
Score: 0.186
-
Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression. Gynecol Oncol. 2019 09; 154(3):524-530.
Score: 0.173
-
Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device. Obstet Gynecol. 2018 01; 131(1):109-116.
Score: 0.155
-
Overall survival after pelvic exenteration for gynecologic malignancy. Gynecol Oncol. 2014 Sep; 134(3):546-51.
Score: 0.122
-
Surgical removal of a gigantic abdominal mass: a multidisciplinary approach. Obstet Gynecol. 2011 Feb; 117(2 Pt 2):508-512.
Score: 0.096
-
Serial cytoreductive surgery and survival outcomes in recurrent adult-type ovarian granulosa cell tumors. Am J Obstet Gynecol. 2024 05; 230(5):544.e1-544.e13.
Score: 0.059
-
Clinical outcomes of leuprolide acetate in the treatment of recurrent ovarian granulosa cell tumors. Am J Obstet Gynecol. 2023 06; 228(6):724.e1-724.e9.
Score: 0.056
-
Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer. Gynecol Oncol. 2021 07; 162(1):24-31.
Score: 0.049
-
The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial. Invest New Drugs. 2021 06; 39(3):829-835.
Score: 0.048
-
Prognostic factors impacting survival in early stage uterine carcinosarcoma. Gynecol Oncol. 2019 01; 152(1):31-37.
Score: 0.041
-
Prospective assessment of patient-reported outcomes in gynecologic cancer patients before and after pelvic exenteration. Gynecol Oncol. 2018 06; 149(3):484-490.
Score: 0.039
-
Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: A window of opportunity study. Gynecol Oncol. 2016 Dec; 143(3):466-471.
Score: 0.036